Nov.2017 – CRI Report

Research Report on China’s Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022

admin — Fri, 17 Aug 2018 09:07:13 +0000

MMR Vaccines Industry Overview

Research by CRI suggests that the sales volume of MMR vaccines exhibited a fluctuating trend in China between 2013 and 2017.

Measles, mumps and rubella are acute respiratory infectious diseases caused by viruses, all of which can be spread through droplets coming from respiratory tracts. Children and teenagers are high risk groups of diseases. Breakout of epidemics among groups will not only result in harms to their health but also have a direct impact on normal teaching orders and even cause social panics.

Measles has the highest incidence rate and mortality rate, posing extremely huge threats to children’s health. People infected with measles usually have clinic manifestations like fever, rashes and cold.

Although rubella and mumps exhibit slight clinic symptoms and favorable prognosis, mumps sometimes brings about serious complications, such as boys with secondary orchitis and girls with secondary ovaritis, further leading to sterility and infertility when they grow up. If women are infected with measles at the early stage of pregnancy, there is a possibility of abortion and fetal malformation.

CRI analyzes that despite reduced incidence rates of measles, rubella and mumps in China in recent years, there is still a big gap between the actual incidence rate of measles and the targeted incidence rate set by WHO, which is required to be less than 1/ 1 million people.

In 2012, China’s incidence rate of measles was recorded the lowest, which was only 4.6/ 1 million people, but this rate has shown an uptrend since 2013. The incidence rates of rubella and mumps demonstrated an overall declining trend between 2012 and 2016.

According to CRI, there have been four mainstream vaccines related to measles, rubella and mumps in China by the end of 2017.

(1) Measles live attenuated vaccines: five enterprises hold production permits.

(2) Measles-mumps combined live attenuated vaccines: two enterprises hold production permits.

(3) Measles-rubella combined live attenuated vaccines: two enterprises hold production permits.

(4) Measles-mumps-rubella combined live attenuated vaccine (measles-mumps-rubella vaccine): two enterprises hold production permits.

In addition, imported measles-mumps-rubella vaccines produced by Glaxo SmithKline are launched into the Chinese market, namely Priorix. Although several enterprises possess production permits of MMR vaccines in China, a part of them have ceased production.

Research by CRI suggests that the sales volume of MMR vaccines exhibited a fluctuating trend in China between 2013 and 2017. This fluctuation is mainly attributed to factors such as government policies and market demand. In 2016, the sales volume of MMR vaccines exceeded 70 million.

The MMR vaccine is gradually taking up the market shares of other vaccines because of its good effect, preventing three types of infectious diseases.
Since 2008, the domestic MMR vaccine has been included in China’s planned immunization, and provided free for children of appropriate ages by the government.

This measure has promoted the development of the MMR vaccine industry in China. From a long-term perspective, MMR vaccines are expected to be the mainstream products, which will gradually substitute monovalent and combined vaccines.

CRI predicts a promising prospect of the MMR vaccine market since the loosing birth control policy is projected to contribute to an annual newborn population of 20 million or more in China during 2018 and 2022. It is estimated that the market shares of MMR vaccines will rise from 70% in 2017 to over 90% in 2022.

Readers can obtain the following information or more through this report:
– Government Policies of China MMR Vaccines
– Supply Status of MMR Vaccines in China
– Lot Release Status of MMR Vaccines
– Demand Status of MMR Vaccines in China
– MMR Vaccine Manufacturers in China
– Competition in China MMR Vaccine Industry
– Market Opportunities and Driving Forces of China MMR Vaccine Industry
– Risks and Challenges Faced by China MMR Vaccine Industry
– Prospect of China MMR Vaccine Market, 2018-2022

Investigation Report on China’s Shingles Vaccine Market 2021-2025

The post Research Report on China’s Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022 first appeared on CRI Report.

Research Report on Blood Product Industry in China, 2018-2022

admin — Fri, 17 Aug 2018 09:05:53 +0000

Description
As a category of biological products, a blood product is a kind of biological active preparation manufactured based on health human blood plasma with biological techniques or plasma separation and purification technologies. According to patients of different diseases, different contents of plasma protein are separated and manufactured into specific blood products. Blood products can be categorized into human serum albumin, human immunoglobulin and coagulation factors that have a widest variety of products.
The concentration rate of global blood product industry is rather high. The four enterprises of developed countries, CSL Behring, Baxter, Grifols and Octapharma, occupy over 80% of global market shares. Currently, the global blood industry maintains relatively stable, with emerging markets serving as major driving forces.
According to CRI, China will become one of the major global blood product markets as its economy develops. Chinese government imposes strict regulations on production, sales and import of blood products. In addition, the government implements a lot release system of biological products (including blood products and vaccines), compulsorily inspecting and verifying every batch of such products when leaving factory or being imported. Disqualified or disapproved products should not be on the market or imported.
According to market research by CRI, about 30 blood product manufacturers have been authenticated by the Chinese government by the end of 2017. But indeed, only 20 of them operate under normal production. Since 2012, mergers and acquisitions have emerged in China’s blood product industry. Examples include Jiangxi Boya Bio-Pharmaceutical Co., Ltd. purchasing partial stake of Zhejiang Haikang Biological Products Co., Ltd., Beijing Tiantan Biological Products Co., Ltd. acquiring Chengdu Rosen Pharmaceutical Co., Ltd. and Humanwell Healthcare Group Co., Ltd. acquiring Wuhan Rui De Biological Products Co., Ltd.
CRI estimates that at least 10,000 tons of blood plasma is needed to meet the demand of Chinese market in 2017, but the actual supply is only 7,000 tons. China’s annual volume of blood plasma represents approximately half of the volume of CSL Behring. In China, the only approach to legal collection of source plasma is plasma collection from blood product manufacturers. There have been less than 300 plasma collection stations in China by the end of 2017, located in 22 domestic regions and belonging to 20 blood product manufacturers. Lack of source plasma collection has always been a major restriction of the development of China’s blood product industry. In China, the competitiveness of blood product manufacturers is mainly determined by the reserve volume of blood plasma. Under the tense condition of source plasma supply, blood product manufacturers have more opportunities for survival and development through obtaining more blood plasma stations and source plasma.
Based on analysis of CRI, the Chinese government imposes strict regulations on the import of blood products despite the lack of local production volume of blood products. Only human serum albumin and reshaped human blood coagulation factor Ⅷ are allowed to be imported. China must rely on the import of human serum albumin due to the demand-supply gap exceeding over 50% in 2017. CSL Behring, Baxter, Grifols S.A. and Octapharma all export human serum albumin to China.
In 2001, the Chinese government announced that new blood product manufacturers would be no longer authenticated for the safety of blood and blood products. If overseas blood product manufacturers desire to enter Chinese market, they can either export their products directly to China or acquire existing blood product manufacturers in China. For example, in August 2017, CSL Behring spent USD 352 million on purchasing 80% stake of Wuhan Zhongyuan Rui De Biological Products Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. On the third of August, 2017, CSL officially announced that it had completed the deal with Humanwell and had taken over business operations of Rui De. CSL Behring temporarily launched only albumin on Chinese market. In order to introduce more products into China, localized production is the first choice. In the future, Rui De is expected to apply extensive expertise of CSL Behring in fields of plasma collection, production and R&D. In the meanwhile, CSL Behring is making efforts to improve the experience of domestic plasma donors. The company also plans to launch more coagulation factor products and establish more plasma collection stations by virtue of Rui De’s knowledge of Chinese market.
Analyzed by CRI, the market value of blood products exceeded CNY 20 billion in China in 2017, with an estimated CAGR of over 10% during 2018 and 2022.
This report is completed on a basis of deep market investigation. Readers can obtain the following information or more through this report:

– Status of Global Blood Product Industry
– Development Status of China Blood Product Industry
– Policy Environment and Lot Release System of China Blood Product Industry
– Status of Segmented China Blood Products
– Competition Status of China Blood Product Industry
– Major Blood Product Manufacturers in China and Their Operation Status
– Blood Products Exported from CSL Behring, Baxter, Grifols S.A. and Octapharma to China, 2013-2017
– Price Trend of Raw Materials and Finished Products in China Blood Product Industry
– Driving Forces and Market Opportunities of China Blood Product Industry, 2018-2022
– Risks and Challenges Faced by China Blood Product Industry, 2018-2022
– Forecast on Supply and Demand of Blood Products in China, 2018-2022

Table of Contents
Chapter I Basic Concept of Blood Products
1.1 Definition of Blood Products
1.2 Classification of Blood Products
1.2.1 Albumin
1.2.2 Immune Globulin
1.2.3 Coagulation Factors
1.2.4 Other Categories
1.3 Research Methods of Report
1.3.1 Parameters and Assumptions
1.3.2 Data Sources
1.3.3 About CRI

Chapter II Overview of Global Blood Product Industry, 2013-2017
2.1 Industry Overview
2.1.1 Development Process
2.1.2 Market Competition
2.1.3 Supply Status
2.1.4 Demand Status
2.2 Major Blood Product Manufacturers in the Globe
2.2.1 CSL Behring
2.2.2 Baxter
2.2.3 Grifols S.A.
2.2.4 Octapharma

Chapter III Operation Status of China Blood Product Industry, 2013-2017
3.1 Development Environment of China Blood Product Industry
3.1.1 Economy Environment
3.1.2 Policy Environment
 Administrative Departments
 Policies on Enterprise Establishment
 Policies on Raw Material Purchasing
 Policies on Blood Product Production
 Policies on Blood Product Circulation
3.1.3 Medical Environment
3.2 Barriers to Entry in China Blood Product Market
3.2.1 Policy Barriers
3.2.2 Blood Source Barriers
3.2.3 Technology and Quality Control Capability
3.3 Analysis on Supply of Blood Products in China, 2013-2017
3.3.1 Overview of Production Status
3.3.2 Analysis of Major Products
3.3.3 Production Capacity and Output Volume of Albumin
3.3.4 Production Capacity and Output Volume of Immunoglobulin
3.3.5 Production Capacity and Output Volume of Coagulation Factors
3.4 Analysis on Demand for Blood Products in China, 2013-2017
3.4.1 Albumin
3.4.2 Immune Globulin
3.4.3 Coagulation Factors
3.5 Competition Pattern of China Blood Product Industry
3.5.1 Bargaining Power of Upstream Suppliers
3.5.2 Bargaining Power of Downstream Clients
3.5.3 Competition in Blood Product Industry
3.5.4 Potential Entrants of Blood Product Industry
3.5.5 Substitutes of Blood Products
3.6 Analysis on Import and Export of Blood Products in China
3.6.1 Import
3.6.2 Export

Chapter IV Analysis of Major Blood Product Manufacturers in China, 2016-2018
4.1 Shanghai RAAS Blood Products Co., Ltd.
4.1.1 Enterprise Profile
4.1.2 Operation Status of Blood Products
(4.2-4.16 are similar to 4.1)
4.2 Hualan Biological Engineering Co., Ltd.
4.3 Beijing Tiantan Biological Products Co., Ltd.
4.4 Zhenxing Biopharmaceutical & Chemical Inc.
4.5 Jiangxi Boya Bio-pharmaceutical Co., Ltd.
4.6 Guangdong Weilun Bio-pharmaceutical Co., Ltd.
4.7 Walvax Biotechnology Co., Ltd.
4.8 Wuhan Rui De Biological Products Co., Ltd.
4.9 Shenzhen Weiguang Biological Products Co., Ltd.
4.10 Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.
4.11 Hunan Nanyue Pharmaceutical Co., Ltd.
4.12 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.13 Green Cross (China) Biological Products Co., Ltd.
4.14 Guiyang Qianfeng Biological Products Co., Ltd.
4.15 Shandong Taibang Products Co., Ltd.
4.16 Subordinate Institutions of Biological Products of China National Biotec Group
4.17 Hebei Daan Pharmaceutical Co., Ltd.
4.18 Guangdong Danxia Bio-pharmaceutical Co., Ltd.
4.19 Harbin Pacific Bio-pharmaceutical Co., Ltd.
4.20 Shanxi Kangbao Biological Product Co., Ltd.

Chapter V Analysis on Blood Product Industry Chain in China, 2016-2018
5.1 Supply of Blood Plasma
5.1.1 Development Status of Plasma Collection Stations in China
5.1.2 Cost of Plasma Collection
5.2 Production of Blood Products
5.2.1 Analysis of Gross Profit Rate
5.2.2 Analysis of Cost Trend
5.3 Price Trend of Blood Products

Chapter VI Forecast on Development of China Blood Product Industry, 2018-2022
6.1 Factors Influencing the Development of China Blood Product Industry
6.1.1 Market Opportunities and Driving Forces
6.1.2 Risks and Challenges
6.2 Forecast on Supply of Blood Products in China, 2018-2022
6.2.1 Forecast on Production Capacity Expansion
6.2.2 Forecast on Lot Release
6.3 Forecast on Demand for Blood Products in China, 2018-2022
6.3.1 Forecast on Demand Trend
6.3.2 Forecast on Market Scale
6.3.3 Forecast on Demand of Niche Markets

Selected Charts
Chart Common Varieties and Functions of Albumin
Chart Common Varieties and Functions of Immune Globulin
Chart Common Varieties and Functions of Coagulation Factors
Chart Global Blood Product Plasma Volume and Forecast, 2012-2022
Chart Global Blood Product Market Scale and Forecast, 2012-2022
Chart Sales Scale of Baxter International Blood Products, 2013-2017
Chart Sales Scale of CSL Behring Blood Products, 2013-2017
Chart Sales Scale of Grifols Blood Products, 2013-2017
Chart Blood Product Plasma Volume in China, 2013-2017
Chart Lot Release Volume of Blood Products in China, 2013-2017
Chart Major Blood Product Manufacturers in China, 2018
Chart Lot Release Volume of Albumin Products in China, 2013-2017
Chart Lot Release Volume of Immune Globulin Products in China, 2013-2017
Chart Lot Release Volume of Coagulation Factor Products in China, 2013-2017
Chart Market Size of China Blood Products, 2013-2017
Chart Market Size of Albumin Blood Products in China, 2013-2017
Chart Market Size of Immune Globulin Blood Products in China, 2013-2017
Chart Products of Shanghai RAAS Blood Products Co. Ltd., 2018
Chart Lot Release Volume of Human Serum Albumin of Shanghai RAAS, 2012-2017
Chart Revenue of Shanghai RAAS Blood Products, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Hualan Biological, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of CSL Behring, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Grifols, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Baxter, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Octapharma, 2013-2017
Chart Quantity of Plasma Collection Stations in China, 2013-2017
Chart Forecast on the Market Size of Blood Products in China, 2018-2022
Chart Forecast on the Market Size of Albumin Products in China, 2018-2022
Chart Forecast on the Market Size of Immune Globulin Products in China, 2018-2022
Chart Forecast on the Market Size of Coagulation Factor Products in China, 2018-2022

The post Research Report on Blood Product Industry in China, 2018-2022 first appeared on CRI Report.